An adapted anti-CTLA4 therapeutic aimed at mitigating the toxicities of checkpoint inhibition

The evolving landscape of N6-methyladenosine modification in the tumor microenvironment

“…programmed cell death-1 (PD-1), programmed cell death-ligand 1 (PD-L1), cytotoxic T lymphocyte antigen 4 (CTLA4), lymphocyte activation gene-3 (LAG-3), T cell immunoglobulin, and immunoreceptor tyrosine-based inhibitory motif (ITIM) domain protein (TI-GIT) and T cell immunoglobulin and mucin domain-3 (TIM-3) (Figure 5). [89][90][91][92][93][94][95][96][97][98][99][100][101][102][103][104] The methylation of RNA and its regulators, especially m 6 A, has an indispensable role in tumor biological activities. Chen and colleagues 105 established m 6 A epigenetic module eigengenes by combining hub m 6 A regulators.…”